ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AGEN vs XFOR // FREE CASH FLOW YIELD

Agenus Inc. (NASDAQ) VS. X4 Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AGEN 3 — XFOR 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGEN VS. XFOR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AGEN XFOR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% 83.60% +12.40 AGEN /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -24.11% — — TIE /fcf-yield <GO>
Operating Margin -17.70% -60.00% +42.30 AGEN /operating-margins <GO>
Net Profit Margin -2.70% -60.00% +57.30 AGEN /net-margins <GO>
Revenue Growth (YoY) 10.40% 180.00% -169.60 XFOR /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.0 60.7 -10.70 XFOR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $320.2M $333.1M -$12.9M XFOR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AGEN REV XFOR REV AGEN GROSS % XFOR GROSS % AGEN FCF XFOR FCF
FY 2025 $114.2M $35.1M 98.0% 83.6% -$77.2M -$85.6M
FY 2024 $103.5M $2.6M 98.0% 68.8% -$158.9M -$131.2M
FY 2023 $156.3M $0 — — -$224.2M -$96.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGEN // BETA —
XFOR // BETA —